ORPHA:423994
Squamous cell carcinoma of the colon
Publications
1,130
Trials
0
Interventional, condition-specific
Researchers
1,248
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare epithelial tumour of the colon arising from squamous cells of the colorectal epithelium without the presence of squamous-lined fistulous tracts or a proximal extension of an anal squamous cell carcinoma. It usually presents with nonspecific symptoms, such as anorexia, weight loss, abdominal pain, changes of bowel habits, hematochesia or melena. Cases of severe, symptomatic hypercalcemia have been reported.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018513
- UMLS:C1333100
- NCIT:C5490
Additional Mondo synonyms (10)
colon epidermoid carcinoma · colon squamous cell cancer · colon squamous cell carcinoma · colonic epidermoid carcinoma · colonic squamous cell carcinoma · epidermoid carcinoma of colon · epidermoid carcinoma of the colon · squamous cell carcinoma of colon · squamous cell carcinoma of the colon · squamous cell colon carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,130 matched papers (809 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 2626 for broader category squamous cell carcinoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,130
1,130 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,130 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
809 in the last 10 years · low confidence
Phrase hits: 1,130 · MeSH hits: 0
Who's working on it?
1,248
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Zhang Y9 papers · 2026
The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China.
Papers in Europe PMC - 02Li J7 papers · 2026
Department of Thoracic Surgery, Institute of Thoracic Surgery, The First Affiliated Hospital of Soochow University, No.899 Pinghai Road, Suzhou, Jiangsu, 215005, China.
Papers in Europe PMC - 03Li X6 papers · 2026
The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China.
Papers in Europe PMC - 04Wang J6 papers · 2026
The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China. wjh@imm.ac.cn.
Papers in Europe PMC - 05Li Y5 papers · 2026
Department of Neurosurgery, Institute of Brain Disease, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.
Papers in Europe PMC - 06Liu X5 papers · 2026
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, China.
Papers in Europe PMC - 07Wang Y5 papers · 2026
Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
Papers in Europe PMC - 08Zhang L5 papers · 2025
Medical College of Soochow University, Suzhou, Jiangsu, 74565, China.
Papers in Europe PMC - 09Chen Y4 papers · 2026
Central laboratory of Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, China.
Papers in Europe PMC - 10Kim S4 papers · 2026
Department of Pathology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, 03080, Seoul, Republic of Korea.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 2,626 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 26 October 2026 · last trial check 26 October 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5498 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
2,626 interventional trials matched squamous cell carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: squamous cell carcinoma
2,626
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05751512·RECRUITING·A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Conditions: Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
- NCT06064877·RECRUITING·A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06052839·RECRUITING·Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)·Matched via name phrase
- NCT06277791·RECRUITING·The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma
Conditions: Clinical IVb Stage Oral Squamous Cell Carcinomas Patients·Matched via name phrase
- NCT06715501·ENROLLING BY INVITATION·Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma · II-IIIB Stages·Matched via name phrase
- NCT07219212·RECRUITING·A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Conditions: Squamous Cell Carcinoma of Head and Neck·Matched via name phrase
- NCT07403630·RECRUITING·INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Conditions: Acute Leukemia · Multiple Myeloma · Squamous Cell Carcinoma · Pleural Mesothelioma·Matched via name phrase
- NCT05495152·RECRUITING·Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07466810·NOT YET RECRUITING·Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology
Conditions: Tongue Squamous Cell Carcinoma · Mixed Reality · Virtual Surgical Planning · Free Flap·Matched via name phrase
- NCT07751341·RECRUITING·A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07425054·RECRUITING·ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer
Conditions: Anal Cancer · HPV-Related Carcinoma · Squamous Cell Carcinoma of the Anus·Matched via name phrase
- NCT07462377·RECRUITING·A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Conditions: Epidermal Growth Factor · Epidermal Growth Factor Receptor · Epidermal Growth Factor Receptor Gene Mutation · Non Small Cell·Matched via name phrase
- NCT07272291·NOT YET RECRUITING·A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name phrase
- NCT06746961·NOT YET RECRUITING·Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
Conditions: Esophageal Squamous Cell Carcinoma (ESCC)·Matched via name phrase
- NCT05085496·RECRUITING·Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
Conditions: Locally Advanced Skin Squamous Cell Carcinoma · Resectable Skin Squamous Cell Carcinoma · Unresectable Skin Squamous Cell Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 14 · after dedupe 14 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 14 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (14)
- isrctn·ISRCTN78380445·Recruiting·A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12839469·No longer recruiting·A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (≥2) lines of therapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11595117·No longer recruiting·A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45319897·No longer recruiting·A study to evaluate the safety, tolerability, processing by the body, and antitumor activity of inavolisib and paclitaxel
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17428671·Stopped·NICO - CA209-891: Neoadjuvant and adjuvant nivolumab as Immune Checkpoint inhibition in Oral cavity cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90009147·No longer recruiting·Trifluridine/tipiracil (FTD/TPI) quality of life study in mCRC patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN97547683·No longer recruiting·Treg Immunotherapy in Crohn’s Disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11233255·No longer recruiting·BUTEO: a clinical trial of BTT1023 in patients with primary sclerosing cholangitis (PSC)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74358648·No longer recruiting·Add-Aspirin: the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN70833965·No longer recruiting·A phase II double-blind, randomised controlled trial of VEGF inhibitor axitinib monotherapy with early dynamic contrast-enhanced ultrasound monitoring in chemo-refractory third-line metastatic colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62704822·No longer recruiting·3D conformal Radiation therapy for Accelerated Partial breast IrraDiation (RAPID) trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN58864837·No longer recruiting·CINATRA: Chromosomal Instability and Anti-Tubulin Response Assessment
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45133151·No longer recruiting·Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99195212·No longer recruiting·An open, randomised, multicentre trial of Tomudex (ZD1694) versus 5-Fluorouracil (5-FU) and Leucovorin (LV) in patients with advanced colorectal carcinoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the colon — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the colon" OR "Squamous cell carcinoma of colon" OR "colon epidermoid carcinoma" OR "colon squamous cell cancer" OR "colon squamous cell carcinoma" OR "colonic epidermoid carcinoma" OR "colonic squamous cell carcinoma" OR "epidermoid carcinoma of colon" OR "epidermoid carcinoma of the colon" OR "squamous cell colon carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the colon" OR "Squamous cell carcinoma of colon" OR "colon epidermoid carcinoma" OR "colon squamous cell cancer" OR "colon squamous cell carcinoma" OR "colonic epidermoid carcinoma" OR "colonic squamous cell carcinoma" OR "epidermoid carcinoma of colon" OR "epidermoid carcinoma of the colon" OR "squamous cell colon carcinoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1130) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T15:54:32.975Z
